Effect of magnesium supplementation in treatment of diabetic hemodialysis patients

Clinical trial of the effect of magnesium supplementation compared with the placebo on carotid intima-media thickness and metabolic profiles in diabetic hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017090133941N19

Enrollment

Registered

2017-11-20

Start date

2017-12-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis. Chronic kidney disease

Interventions

Intervention 1: Intervention group: 250 mg magnesium (21st Century Pharmaceutical Company, Arizona, USA), daily for 24 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Diabetic hemodialysis patients Aged 18 to 80 years

Exclusion criteria

Exclusion criteria: Patients with inflammatory and malignant diseases Taking magnesium supplements, antioxidant and/or anti-inflammatory supplements within 3 months prior to enrollment in the study Taking immunosuppressive agents

Design outcomes

Primary

Measure	Time frame
Maximum right CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Mean left CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Maximum left CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Mean right CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.	—

Measure

Time frame

Maximum right CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Mean left CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Maximum left CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.;Mean right CIMT. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Sonography.

—

Secondary

Measure	Time frame
Insulin. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Triglycerides. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Insulin. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Triglycerides. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026